Medical and surgical treatment of parapneumonic effusions - An evidence-based guideline

被引:395
作者
Colicc, GL
Curtis, A
Deslauriers, J
Heffner, J
Light, R
Littenberg, B
Sahn, S
Weinstein, RA
Yusen, RD
机构
[1] Washington Hosp Ctr, Pulm Serv, Washington, DC 20010 USA
[2] Washington Hosp Ctr, Resp Serv, Washington, DC 20010 USA
[3] Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06520 USA
[4] Hop Laval, Ctr Pneumol, Dept Thorac Surg, Laval, PQ, Canada
[5] Univ S Carolina, Dept Med, Columbia, SC 29208 USA
[6] Vanderbilt Univ, Dept Med, Nashville, TN USA
[7] Univ Vermont, Dept Med, Burlington, VT 05405 USA
[8] Rush Med Coll, Dept Med, Chicago, IL 60612 USA
关键词
empyema; fibrinolytics; parapneumonic effusion; thoracentesis;
D O I
10.1378/chest.118.4.1158
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: A panel was convened by the Health and Science Policy Committee of the American College of Chest Physicians to develop a clinical practice guideline on the medical and surgical treatment of parapneumonic effusions (PPE) using evidence-based methods. Options and outcomes considered: Based on consensus of clinical opinion, the expert panel developed an annotated table for evaluating the risk for poor outcome in patients with PPE. Estimates of the risk for poor outcome were based on the clinical judgment that, without adequate drainage of the pleural space, the patient,vith PPE would be likely to have any or all of the following: prolonged hospitalization, prolonged evidence of systemic toxicity, increased morbidity from any drainage procedure, increased risk for residual ventilatory impairment, increased risk for local spread of the inflammatory reaction, and increased mortality. Three variables, pleural space anatomy, pleural fluid bacteriology, and pleural fluid chemistry, were used in this annotated table to categorize patients into four separate risk levels for poor outcome: categories 1 (very low risk), 2 (low risk), 3 (moderate risk), and (high risk). The panel's consensus opinion supported drainage for patients with moderate (category 3) or high (category 4) risk for a poor outcome, but not for patients with very low (category 1) or low (category 2) risk for a poor outcome. The medical literature was reviewed to evaluate the effectiveness of medical and surgical management approaches for patients with PPE at moderate or high risk for poor outcome. The panel grouped PPE management approaches into six categories: no drainage performed, therapeutic thoracentesis, tube thoracostomy, fibrinolytics, video-assisted thoracoscopic surgery (VATS), and surgery (including thoracotomy with or without decortication and rib resection). The fibrinolytic approach required tube thoracostomy for administration of drug, and VATS included postprocedure tube thoracostomy. Surgery may have included concomitant lung resection and always included postoperative tube thoracostomy. All management approaches included appropriate treatment of the underlying pneumonia, including systemic antibiotics. Criteria for including articles in the panel review were adequate data provided for greater than or equal to 20 adult patients with PPE to allow evaluation of at least one relevant outcome (death or need for a second intervention to manage the PPE); reasonable assurance provided that drainage was clinically appropriate (patients receiving drainage were either category 3 or category 4) and drainage procedure was adequately described; and original data were presented. The strength of panel recommendations on management of PPE was based on the following approach: level A, randomized, controlled trials with consistent results or individual randomized, controlled trial with narrow confidence interval (CI); level B, controlled cohort and case control series; level C, historically controlled series and case series; and level D, expert ol,inion without explicit critical appraisal or based on physiology, bench research, or "first principles."
引用
收藏
页码:1158 / 1171
页数:14
相关论文
共 41 条
[1]   MANAGEMENT OF EMPYEMA THORACIS [J].
ALI, I ;
UNRUH, H .
ANNALS OF THORACIC SURGERY, 1990, 50 (03) :355-359
[2]   PLEURAL EXUDATES AND TRANSUDATES - DIAGNOSIS WITH CONTRAST-ENHANCED CT [J].
AQUINO, SL ;
WEBB, WR ;
GUSHIKEN, BJ .
RADIOLOGY, 1994, 192 (03) :803-808
[3]   RECENT TRENDS IN EMPYEMA THORACIS [J].
BENFIELD, GFA .
BRITISH JOURNAL OF DISEASES OF THE CHEST, 1981, 75 (04) :358-366
[4]   IMMEDIATE DRAINAGE IS NOT REQUIRED FOR ALL PATIENTS WITH COMPLICATED PARAPNEUMONIC EFFUSIONS [J].
BERGER, HA ;
MORGANROTH, ML .
CHEST, 1990, 97 (03) :731-735
[5]   Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema - A randomized, double-blind study [J].
Bouros, D ;
Schiza, S ;
Tzanakis, N ;
Chalkiadakis, C ;
Drositis, J ;
Siafakas, N .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (01) :37-42
[6]   Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions - A prospective, double-blind study [J].
Bouros, D ;
Schiza, S ;
Patsourakis, G ;
Chalkiadakis, G ;
Panagou, P ;
Siafakas, NM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (01) :291-295
[7]   Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip [J].
Cheng, DS ;
Rodriguez, RM ;
Rogers, J ;
Wagster, M ;
Starnes, DL ;
Light, RW .
CHEST, 1998, 114 (05) :1368-1372
[8]   Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions [J].
Chin, NK ;
Lim, TK .
CHEST, 1997, 111 (02) :275-279
[9]  
COHN LH, 1970, ARCH SURG-CHICAGO, V100, P376
[10]   Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection [J].
Davies, RJO ;
Traill, ZC ;
Gleeson, FV .
THORAX, 1997, 52 (05) :416-421